The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Study critique

Coming back to: A critique that turned out to be unfair, retracted by its author

Closed
IA
i.amankwahTL2 Moderator22 Mar 2025#1

A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable.

I have seen STEP 4 (JAMA, 2021) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

36 likes 16mo
QL
quiet_lurkerTL2Regular23 Apr 2025#2

When you change your mind: if a reply convinces you that your criticism was not well-founded, say so plainly. The critique might still be real but smaller than you originally thought. That is not a failure — it is how discussion works.

8 likes 15mo
JB
j.bhattacharyaTL2 Moderator15 May 2025 · edited#3
i.amankwah, post #1: A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is that the trial is sound… Go to post

Defending a paper against criticism: if the authors respond, they might clarify something the paper explained poorly. Their response might also miss your point. Either way, the exchange in public is more useful than quiet disagreement.

2 likes in reply to #1 14mo
This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
A well-designed study with a badly written abstract — does this still hold?
A well-designed study with a badly written abstract — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J Med , 2021)…
ENCEKA 2 28k 20mo
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
VRRIJV 2 6.9k 14mo
A claim built entirely on a subgroup analysis — what changed since
On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
AWZCQZ 2 2k 18mo
Reverse causation in a cohort study of weight and outcome — a second dataset
Reverse causation in a cohort study of weight and outcome — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
MRAKANKBVK+112 131 1.5k 10mo
Immortal time bias in a claims-database study
Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
MACDSOIDNN+29 34 28k 11mo

Related topics — sharing the tags disputed, observational data, effect size

TopicParticipantsRepliesViewsActivity
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J…
SCHJSATKO+23 27 9.9k 1mo
Distinguishing a red flag from an inconvenience
Distinguishing a red flag from an inconvenience — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately from product…
ASJMIT 2 38k 6mo
Heterogeneity as information rather than as a nuisance
Posting this under the heading it deserves: Heterogeneity as information rather than as a nuisance Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
DFRJMNAN+88 95 1.2k 6mo
Evidence quality in the secretagogue literature: an honest assessment
Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP…
SSSVK 2 25k 9d
Correlation in a self-tracked dataset: what it can support
Correlation in a self-tracked dataset: what it can support — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
IDMYLMEKN+152 166 48k 23mo